Rejean Fortin

2-Pyridinyl-3-(4-methylsulfonyl)phenylpyridines: Selective and orally active cyclooxygenase-2 inhibitors

A series of novel 2-pyridinyl-3-(4-methylsulfonyl)phenylpyridines has been synthesized and evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1, and COX-2. Optimum COX-2 activity is observed by introduction of a substituent at C5 of the central pyridine. 5- Chloro-3-(4-methylsulfonyl)phenyl-2-(2-methyl-5-pyridinyl)pyridine 33 was identified as the optimum compound in this series.

Pharmacology of L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpropanoic acid); a potent, selective thromboxane/prostaglandin endoperoxide antagonist

L-655,240 (3-[1-(4-chlorobenzyl)-5-fluoro-3-methyl-indol-2-yl]2,2-dimethylpropa noic acid) has been studied in vitro on the guinea-pig tracheal chain, pulmonary artery and thoracic aorta ring and shown to be a potent, competitive antagonist of contractions induced by the prostaglandin endoperoxide analogue, U-44069 (pA2 values 8.0, 8.4 and 8.0 respectively). Selectivity on the guinea-pig trachea was indicated by non-competitive antagonism of contractions induced by prostaglandin D2 and minimal activity against contractions induced by leukotriene D4, prostaglandin F2 alpha, serotonin, histamine and acetylcholine. L-655,240 was a potent inhibitor of the aggregation of washed human platelets induced by U-44069 (IC50 value 7 X 10(-9) M) and inhibited aggregation of human platelet rich plasma induced by U-44069, U-46619, thromboxane A2 and collagen but not ADP or platelet activating factor. In vivo i.v. L-655,240 administered to guinea-pigs inhibited bronchoconstriction induced by i.v. U-44069 and arachidonic acid (ED50 values 0.09 and 0.23 mg kg-1) but not histamine, acetylcholine or serotonin. When administered to rhesus monkeys (3 and 10 mg/kg p.o.), L-655,240 inhibited ex vivo platelet aggregation induced by U-44069 but not ADP. It is concluded that L-655,240 is a potent, selective, orally active thromboxane/prostaglandin endoperoxide antagonist.

tert-Butylmethoxyphenylsilyl ether - a new selective, stable alcohol protecting group with remarkable lability to fluoride.

Abstract tert -Butylmethoxyphenylsilyl ethers, which can be formed from primary, secondary or tertiary alcohols and tert -butylmethoxyphenylsilyl bromide, are selectively cleaved by fluoride in the presence of other silyl ethers.

NOVEL 1,2-DIARYLCYCLOBUTENES : SELECTIVE AND ORALLY ACTIVE COX-2 INHIBITORS

A series of novel 2,3-diaryl-2-cyclobuten-l-ones have been synthesized and have been evaluated with respect to their ability to inhibit the isozymes of cyclooxygenase, COX-1 and COX-2. 4,4-Dimethyl-2- phenyl-3-(4-(methylsulfonyl)phenyl)cyclobutenone 22 was found to be highly selective for inhibition of COX-2 and was orally active (EDs0 = 2.4 mg/kg) in the rat paw edema model. Copyright

The unsymmetrical silaketal as a neutral, removable tether for effecting intramolecular diels-alder reactions.

Abstract Silaketals, in which reactive dienes and dienophiles are linked, can participate in intramolecular Diels-Alder reactions to produce products with a high degree of stereocontrol and with regiochemistry opposite to that predicted by bond polarization models.

Structure–activity relationships and pharmacokinetic parameters of quinoline acylsulfonamides as potent and selective antagonists of the EP4 receptor

A new series of EP(4) antagonists based on a quinoline acylsulfonamide scaffold have been identified as part of our on-going efforts to develop treatments for chronic inflammation. These compounds show subnanomolar intrinsic binding potency towards the EP(4) receptor, and excellent selectivity towards other prostanoid receptors. Acceptable pharmacokinetic profiles have also been demonstrated across a series of preclinical species.

2-Heterosubstituted-3-(4-methylsulfonyl)phenyl-5-trifluoromethyl pyridines as selective and orally active cyclooxygenase-2 inhibitors

A series of novel 2-alkoxy, 2-thioalkoxy and 2-amino-3-(4-methylsulfonyl)phenylpyridines has been synthesized and shown to be highly potent and selective cyclooxygenase-2 (COX-2) inhibitors. Structure-activity relationship studies have demonstrated that central pyridine ring substituents play an important role in the COX-2 potency, selectivity vs the COX-1 enzyme, and oral activity.

A new class of leukotriene biosynthesis inhibitors: The discovery of MK0591

Abstract The evolution of a quinoline based FLAP inhibitor, L-674,636, into a novel quinoline-indole hybrid compound: MK0591, is described. The new series of compounds are more potent, particularly in binding to FLAP, in inhibiting LTB4 biosynthesis in stimulated human PMN, and in the human whole blood assay.

Identification of a new biaryl scaffold generating potent renin inhibitors.

The discovery and SAR of a series of potent renin inhibitors possessing a novel biaryl scaffold are described herein. Molecular modeling revealed that the cyclopropylamide spacer present in 1 can be replaced by a simple, substituted aromatic ring such as a toluene in 2. The resulting compounds exhibit subnanomolar renin IC(50) and good oral bioavailability in rats.

New preparation of N(1)- and N(2)- alkylated tetrazoles via displacement of activated alcohols

Abstract A facile and convenient synthesis of N(1)- and N(2)-alkyltetrazoles is described. Tetrazole in the presence of zinc triflate reacts smoothly with activated alcohols to give the corresponding alkyltetrazole in high yield.